These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210 [TBL] [Abstract][Full Text] [Related]
9. In brief: poor metabolizers of clopidogrel (plavix). Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520 [No Abstract] [Full Text] [Related]
10. Cytochrome P-450 polymorphisms and response to clopidogrel. Taubert D; Bouman HJ; van Werkum JW N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375 [No Abstract] [Full Text] [Related]
11. Duration of clopidogrel therapy with drug-eluting stents. Rennings AJ; Schouwenberg BJ; van Onzenoort HA N Engl J Med; 2010 Jul; 363(5):489; author reply 490. PubMed ID: 20830829 [No Abstract] [Full Text] [Related]
12. [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. Galiavich AS; Valeeva DD; Minnetdinov RSh; Arkhipova AA; Akhmetov II; Galiavi RA Kardiologiia; 2012; 52(4):20-4. PubMed ID: 22839512 [TBL] [Abstract][Full Text] [Related]
13. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient). Wynn RL Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886 [No Abstract] [Full Text] [Related]
14. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880 [TBL] [Abstract][Full Text] [Related]
15. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. Hulot JS; Wuerzner G; Bachelot-Loza C; Azizi M; Blanchard A; Peyrard S; Funck-Brentano C; Gaussem P J Thromb Haemost; 2010 Mar; 8(3):610-3. PubMed ID: 20040040 [No Abstract] [Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR; Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271 [TBL] [Abstract][Full Text] [Related]
17. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. Gurbel PA; Tantry US; Shuldiner AR JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051 [No Abstract] [Full Text] [Related]
18. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Steinhubl SR Circulation; 2010 Feb; 121(4):481-3. PubMed ID: 20083686 [No Abstract] [Full Text] [Related]
19. Clopidogrel pharmacogenetics: metabolism and drug interactions. Close SL Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266 [TBL] [Abstract][Full Text] [Related]